Long-term outcomes of a therapist-supported, smartphone-based intervention for elevated symptoms of depression and anxiety: Quasiexperimental, pre-postintervention study

Marcos Economides, Kristian Ranta, Albert Nazander, Outi Hilgert, Philippe R. Goldin, Anu Raevuori, Valerie Forman-Hoffman

Research output: Contribution to journalArticle

Abstract

Background: Depression is one of the most common mental health disorders and severely impacts one’s physical, psychological, and social functioning. To address access barriers to care, we developed Ascend—a smartphone-delivered, therapist-supported, 8-week intervention based on several evidence-based psychological treatments for depression and anxiety. A previous feasibility study with 102 adults with elevated depression reported that Ascend is associated with a postintervention reduction in depression symptoms. Objective: We aimed to examine whether Ascend is associated with a reduction in symptoms of anxiety, and importantly, whether reductions in symptoms of depression and anxiety are maintained up to 12-months postintervention. Methods: We assessed whether the previously reported, end-of-treatment improvements seen in the 102 adults with elevated symptoms of depression extended up to 12 months posttreatment for depression symptoms (measured by the Patient Health Questionnaire-9 [PHQ-9]) and up to 6 months posttreatment for anxiety symptoms (added to the intervention later and measured using the Generalized Anxiety Disorder-7 [GAD-7] scale). We used linear mixed effects models with Tukey contrasts to compare time points and reported intention-to-treat statistics with a sensitivity analysis. Results: The intervention was associated with reductions in symptoms of depression that were maintained 12 months after the program (6.67-point reduction in PHQ-9 score, 95% CI 5.59-7.75; P<.001; Hedges g=1.14, 95% CI 0.78-1.49). A total of 60% of the participants with PHQ-9 scores above the cutoff for major depression at baseline (PHQ≥10) reported clinically significant improvement at the 12-month follow-up (at least 50% reduction in PHQ-9 score and postprogram score <10). Participants also reported reductions in symptoms of anxiety that were maintained for at least 6 months after the program (4.26-point reduction in GAD-7 score, 95% CI 3.14-5.38; P<.001; Hedges g=0.91, 95% CI 0.54-1.28). Conclusions: There is limited evidence on whether outcomes associated with smartphone-based interventions for common mental health problems are maintained posttreatment. Participants who enrolled in Ascend experienced clinically significant reductions in symptoms of depression and anxiety that were maintained for up to 1 year and 6 months after the intervention, respectively. Future randomized trials are warranted to test Ascend as a scalable solution to the treatment of depression and anxiety.

Original languageEnglish (US)
Article numbere14284
JournalJMIR mHealth and uHealth
Volume7
Issue number8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Anxiety
Depression
Health
Anxiety Disorders
Mental Health
Smartphone
Psychology
Feasibility Studies
Mental Disorders
Therapeutics
Surveys and Questionnaires

Keywords

  • Anxiety
  • CBT
  • Depression
  • Digital health
  • Mindfulness
  • Online intervention
  • Smartphone intervention

ASJC Scopus subject areas

  • Health Informatics

Cite this

Long-term outcomes of a therapist-supported, smartphone-based intervention for elevated symptoms of depression and anxiety : Quasiexperimental, pre-postintervention study. / Economides, Marcos; Ranta, Kristian; Nazander, Albert; Hilgert, Outi; Goldin, Philippe R.; Raevuori, Anu; Forman-Hoffman, Valerie.

In: JMIR mHealth and uHealth, Vol. 7, No. 8, e14284, 01.01.2019.

Research output: Contribution to journalArticle

Economides, Marcos ; Ranta, Kristian ; Nazander, Albert ; Hilgert, Outi ; Goldin, Philippe R. ; Raevuori, Anu ; Forman-Hoffman, Valerie. / Long-term outcomes of a therapist-supported, smartphone-based intervention for elevated symptoms of depression and anxiety : Quasiexperimental, pre-postintervention study. In: JMIR mHealth and uHealth. 2019 ; Vol. 7, No. 8.
@article{f852ebd616874da992ac0db9221c7915,
title = "Long-term outcomes of a therapist-supported, smartphone-based intervention for elevated symptoms of depression and anxiety: Quasiexperimental, pre-postintervention study",
abstract = "Background: Depression is one of the most common mental health disorders and severely impacts one’s physical, psychological, and social functioning. To address access barriers to care, we developed Ascend—a smartphone-delivered, therapist-supported, 8-week intervention based on several evidence-based psychological treatments for depression and anxiety. A previous feasibility study with 102 adults with elevated depression reported that Ascend is associated with a postintervention reduction in depression symptoms. Objective: We aimed to examine whether Ascend is associated with a reduction in symptoms of anxiety, and importantly, whether reductions in symptoms of depression and anxiety are maintained up to 12-months postintervention. Methods: We assessed whether the previously reported, end-of-treatment improvements seen in the 102 adults with elevated symptoms of depression extended up to 12 months posttreatment for depression symptoms (measured by the Patient Health Questionnaire-9 [PHQ-9]) and up to 6 months posttreatment for anxiety symptoms (added to the intervention later and measured using the Generalized Anxiety Disorder-7 [GAD-7] scale). We used linear mixed effects models with Tukey contrasts to compare time points and reported intention-to-treat statistics with a sensitivity analysis. Results: The intervention was associated with reductions in symptoms of depression that were maintained 12 months after the program (6.67-point reduction in PHQ-9 score, 95{\%} CI 5.59-7.75; P<.001; Hedges g=1.14, 95{\%} CI 0.78-1.49). A total of 60{\%} of the participants with PHQ-9 scores above the cutoff for major depression at baseline (PHQ≥10) reported clinically significant improvement at the 12-month follow-up (at least 50{\%} reduction in PHQ-9 score and postprogram score <10). Participants also reported reductions in symptoms of anxiety that were maintained for at least 6 months after the program (4.26-point reduction in GAD-7 score, 95{\%} CI 3.14-5.38; P<.001; Hedges g=0.91, 95{\%} CI 0.54-1.28). Conclusions: There is limited evidence on whether outcomes associated with smartphone-based interventions for common mental health problems are maintained posttreatment. Participants who enrolled in Ascend experienced clinically significant reductions in symptoms of depression and anxiety that were maintained for up to 1 year and 6 months after the intervention, respectively. Future randomized trials are warranted to test Ascend as a scalable solution to the treatment of depression and anxiety.",
keywords = "Anxiety, CBT, Depression, Digital health, Mindfulness, Online intervention, Smartphone intervention",
author = "Marcos Economides and Kristian Ranta and Albert Nazander and Outi Hilgert and Goldin, {Philippe R.} and Anu Raevuori and Valerie Forman-Hoffman",
year = "2019",
month = "1",
day = "1",
doi = "10.2196/14284",
language = "English (US)",
volume = "7",
journal = "JMIR mHealth and uHealth",
issn = "2291-5222",
publisher = "Journal of medical Internet Research",
number = "8",

}

TY - JOUR

T1 - Long-term outcomes of a therapist-supported, smartphone-based intervention for elevated symptoms of depression and anxiety

T2 - Quasiexperimental, pre-postintervention study

AU - Economides, Marcos

AU - Ranta, Kristian

AU - Nazander, Albert

AU - Hilgert, Outi

AU - Goldin, Philippe R.

AU - Raevuori, Anu

AU - Forman-Hoffman, Valerie

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Depression is one of the most common mental health disorders and severely impacts one’s physical, psychological, and social functioning. To address access barriers to care, we developed Ascend—a smartphone-delivered, therapist-supported, 8-week intervention based on several evidence-based psychological treatments for depression and anxiety. A previous feasibility study with 102 adults with elevated depression reported that Ascend is associated with a postintervention reduction in depression symptoms. Objective: We aimed to examine whether Ascend is associated with a reduction in symptoms of anxiety, and importantly, whether reductions in symptoms of depression and anxiety are maintained up to 12-months postintervention. Methods: We assessed whether the previously reported, end-of-treatment improvements seen in the 102 adults with elevated symptoms of depression extended up to 12 months posttreatment for depression symptoms (measured by the Patient Health Questionnaire-9 [PHQ-9]) and up to 6 months posttreatment for anxiety symptoms (added to the intervention later and measured using the Generalized Anxiety Disorder-7 [GAD-7] scale). We used linear mixed effects models with Tukey contrasts to compare time points and reported intention-to-treat statistics with a sensitivity analysis. Results: The intervention was associated with reductions in symptoms of depression that were maintained 12 months after the program (6.67-point reduction in PHQ-9 score, 95% CI 5.59-7.75; P<.001; Hedges g=1.14, 95% CI 0.78-1.49). A total of 60% of the participants with PHQ-9 scores above the cutoff for major depression at baseline (PHQ≥10) reported clinically significant improvement at the 12-month follow-up (at least 50% reduction in PHQ-9 score and postprogram score <10). Participants also reported reductions in symptoms of anxiety that were maintained for at least 6 months after the program (4.26-point reduction in GAD-7 score, 95% CI 3.14-5.38; P<.001; Hedges g=0.91, 95% CI 0.54-1.28). Conclusions: There is limited evidence on whether outcomes associated with smartphone-based interventions for common mental health problems are maintained posttreatment. Participants who enrolled in Ascend experienced clinically significant reductions in symptoms of depression and anxiety that were maintained for up to 1 year and 6 months after the intervention, respectively. Future randomized trials are warranted to test Ascend as a scalable solution to the treatment of depression and anxiety.

AB - Background: Depression is one of the most common mental health disorders and severely impacts one’s physical, psychological, and social functioning. To address access barriers to care, we developed Ascend—a smartphone-delivered, therapist-supported, 8-week intervention based on several evidence-based psychological treatments for depression and anxiety. A previous feasibility study with 102 adults with elevated depression reported that Ascend is associated with a postintervention reduction in depression symptoms. Objective: We aimed to examine whether Ascend is associated with a reduction in symptoms of anxiety, and importantly, whether reductions in symptoms of depression and anxiety are maintained up to 12-months postintervention. Methods: We assessed whether the previously reported, end-of-treatment improvements seen in the 102 adults with elevated symptoms of depression extended up to 12 months posttreatment for depression symptoms (measured by the Patient Health Questionnaire-9 [PHQ-9]) and up to 6 months posttreatment for anxiety symptoms (added to the intervention later and measured using the Generalized Anxiety Disorder-7 [GAD-7] scale). We used linear mixed effects models with Tukey contrasts to compare time points and reported intention-to-treat statistics with a sensitivity analysis. Results: The intervention was associated with reductions in symptoms of depression that were maintained 12 months after the program (6.67-point reduction in PHQ-9 score, 95% CI 5.59-7.75; P<.001; Hedges g=1.14, 95% CI 0.78-1.49). A total of 60% of the participants with PHQ-9 scores above the cutoff for major depression at baseline (PHQ≥10) reported clinically significant improvement at the 12-month follow-up (at least 50% reduction in PHQ-9 score and postprogram score <10). Participants also reported reductions in symptoms of anxiety that were maintained for at least 6 months after the program (4.26-point reduction in GAD-7 score, 95% CI 3.14-5.38; P<.001; Hedges g=0.91, 95% CI 0.54-1.28). Conclusions: There is limited evidence on whether outcomes associated with smartphone-based interventions for common mental health problems are maintained posttreatment. Participants who enrolled in Ascend experienced clinically significant reductions in symptoms of depression and anxiety that were maintained for up to 1 year and 6 months after the intervention, respectively. Future randomized trials are warranted to test Ascend as a scalable solution to the treatment of depression and anxiety.

KW - Anxiety

KW - CBT

KW - Depression

KW - Digital health

KW - Mindfulness

KW - Online intervention

KW - Smartphone intervention

UR - http://www.scopus.com/inward/record.url?scp=85074266394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074266394&partnerID=8YFLogxK

U2 - 10.2196/14284

DO - 10.2196/14284

M3 - Article

AN - SCOPUS:85074266394

VL - 7

JO - JMIR mHealth and uHealth

JF - JMIR mHealth and uHealth

SN - 2291-5222

IS - 8

M1 - e14284

ER -